#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Stroke-associated pneumonia ( SAP ) is defined as a spectrum of lower respiratory infections within the first 7 days of stroke onset .
3-1	17-34	Stroke-associated	abstract[3]	new[3]	appos	3-4[0_3]
3-2	35-44	pneumonia	abstract[3]	new[3]	_	_
3-3	45-46	(	_	_	_	_
3-4	47-50	SAP	abstract	giv	ana	4-1
3-5	51-52	)	_	_	_	_
3-6	53-55	is	_	_	_	_
3-7	56-63	defined	_	_	_	_
3-8	64-66	as	_	_	_	_
3-9	67-68	a	_	_	_	_
3-10	69-77	spectrum	_	_	_	_
3-11	78-80	of	_	_	_	_
3-12	81-86	lower	abstract[5]	new[5]	coref	4-5[11_5]
3-13	87-98	respiratory	abstract[5]	new[5]	_	_
3-14	99-109	infections	abstract[5]	new[5]	_	_
3-15	110-116	within	_	_	_	_
3-16	117-120	the	time[6]	new[6]	_	_
3-17	121-126	first	time[6]	new[6]	_	_
3-18	127-128	7	time[6]	new[6]	_	_
3-19	129-133	days	time[6]	new[6]	_	_
3-20	134-136	of	time[6]	new[6]	_	_
3-21	137-143	stroke	time[6]|event|event[8]	new[6]|new|new[8]	coref|coref	6-1|6-1
3-22	144-149	onset	time[6]|event[8]	new[6]|new[8]	_	_
3-23	150-151	.	_	_	_	_

#Text=It is one of the most frequent post-stroke infections affecting 14 % of patients and is associated with a three-fold increase in hospital mortality , prolonged hospital stay and poor functional outcomes .
4-1	152-154	It	abstract	giv	coref	5-4
4-2	155-157	is	_	_	_	_
4-3	158-161	one	abstract[10]	new[10]	_	_
4-4	162-164	of	abstract[10]	new[10]	_	_
4-5	165-168	the	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
4-6	169-173	most	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
4-7	174-182	frequent	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
4-8	183-194	post-stroke	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
4-9	195-205	infections	abstract[10]|abstract[11]	new[10]|giv[11]	_	_
4-10	206-215	affecting	_	_	_	_
4-11	216-218	14	quantity[12]	new[12]	_	_
4-12	219-220	%	quantity[12]	new[12]	_	_
4-13	221-223	of	quantity[12]	new[12]	_	_
4-14	224-232	patients	quantity[12]|person	new[12]|new	coref	7-9[37_0]
4-15	233-236	and	_	_	_	_
4-16	237-239	is	_	_	_	_
4-17	240-250	associated	_	_	_	_
4-18	251-255	with	_	_	_	_
4-19	256-257	a	abstract[14]	new[14]	_	_
4-20	258-268	three-fold	abstract[14]	new[14]	_	_
4-21	269-277	increase	abstract[14]	new[14]	_	_
4-22	278-280	in	abstract[14]	new[14]	_	_
4-23	281-289	hospital	abstract[14]|place|abstract[16]	new[14]|new|new[16]	coref|coref	4-27|4-27
4-24	290-299	mortality	abstract[14]|abstract[16]	new[14]|new[16]	_	_
4-25	300-301	,	_	_	_	_
4-26	302-311	prolonged	_	_	_	_
4-27	312-320	hospital	place|time[18]	giv|new[18]	coref|coref	8-24|8-24
4-28	321-325	stay	time[18]	new[18]	_	_
4-29	326-329	and	_	_	_	_
4-30	330-334	poor	event[19]	new[19]	coref	15-16[137_19]
4-31	335-345	functional	event[19]	new[19]	_	_
4-32	346-354	outcomes	event[19]	new[19]	_	_
4-33	355-356	.	_	_	_	_

#Text=The pathophysiology of SAP is multifactorial .
5-1	357-360	The	abstract[20]	new[20]	_	_
5-2	361-376	pathophysiology	abstract[20]	new[20]	_	_
5-3	377-379	of	abstract[20]	new[20]	_	_
5-4	380-383	SAP	abstract[20]|abstract	new[20]|giv	coref	6-22
5-5	384-386	is	_	_	_	_
5-6	387-401	multifactorial	_	_	_	_
5-7	402-403	.	_	_	_	_

#Text=Stroke induced immunosuppression , aspiration of oropharyngeal secretions and stomach contents , related to impaired consciousness and dysphagia increase vulnerability to SAP in the acute phase .
6-1	404-410	Stroke	abstract	giv	coref	7-9
6-2	411-418	induced	_	_	_	_
6-3	419-436	immunosuppression	abstract|abstract[24]	new|new[24]	coref|coref|coref|coref	17-15[149_0]|17-15[150_24]|17-15[149_0]|17-15[150_24]
6-4	437-438	,	abstract[24]	new[24]	_	_
6-5	439-449	aspiration	abstract[24]|abstract[25]	new[24]|new[25]	coref	7-20[42_25]
6-6	450-452	of	abstract[24]|abstract[25]	new[24]|new[25]	_	_
6-7	453-466	oropharyngeal	abstract[24]|abstract[25]|substance[26]	new[24]|new[25]|new[26]	_	_
6-8	467-477	secretions	abstract[24]|abstract[25]|substance[26]	new[24]|new[25]|new[26]	_	_
6-9	478-481	and	abstract[24]|abstract[25]	new[24]|new[25]	_	_
6-10	482-489	stomach	abstract[24]|abstract[25]|abstract|object[28]	new[24]|new[25]|new|new[28]	_	_
6-11	490-498	contents	abstract[24]|abstract[25]|object[28]	new[24]|new[25]|new[28]	_	_
6-12	499-500	,	_	_	_	_
6-13	501-508	related	_	_	_	_
6-14	509-511	to	_	_	_	_
6-15	512-520	impaired	abstract[29]	new[29]	_	_
6-16	521-534	consciousness	abstract[29]	new[29]	_	_
6-17	535-538	and	_	_	_	_
6-18	539-548	dysphagia	abstract[30]	new[30]	_	_
6-19	549-557	increase	abstract[30]	new[30]	_	_
6-20	558-571	vulnerability	abstract[30]	new[30]	_	_
6-21	572-574	to	abstract[30]	new[30]	_	_
6-22	575-578	SAP	abstract[30]|abstract	new[30]|giv	coref	7-15
6-23	579-581	in	abstract[30]	new[30]	_	_
6-24	582-585	the	abstract[30]|abstract[32]	new[30]|new[32]	_	_
6-25	586-591	acute	abstract[30]|abstract[32]	new[30]|new[32]	_	_
6-26	592-597	phase	abstract[30]|abstract[32]	new[30]|new[32]	_	_
6-27	598-599	.	_	_	_	_

#Text=Dysphagia occurs in 37 – 78 % of stroke patients and increases risk of pneumonia 11-fold in patients with confirmed aspiration .
7-1	600-609	Dysphagia	abstract	new	coref	8-35
7-2	610-616	occurs	_	_	_	_
7-3	617-619	in	_	_	_	_
7-4	620-622	37	quantity	new	_	_
7-5	623-624	–	_	_	_	_
7-6	625-627	78	quantity[35]	new[35]	_	_
7-7	628-629	%	quantity[35]	new[35]	_	_
7-8	630-632	of	quantity[35]	new[35]	_	_
7-9	633-639	stroke	quantity[35]|event|person[37]	new[35]|giv|giv[37]	coref|coref|coref|coref	7-18[41_37]|8-14[47_0]|7-18[41_37]|8-14[47_0]
7-10	640-648	patients	quantity[35]|person[37]	new[35]|giv[37]	_	_
7-11	649-652	and	_	_	_	_
7-12	653-662	increases	_	_	_	_
7-13	663-667	risk	abstract[38]	new[38]	_	_
7-14	668-670	of	abstract[38]	new[38]	_	_
7-15	671-680	pneumonia	abstract[38]|abstract|abstract[40]	new[38]|giv|new[40]	coref|coref	9-15|9-15
7-16	681-688	11-fold	abstract[38]|abstract[40]	new[38]|new[40]	_	_
7-17	689-691	in	abstract[38]|abstract[40]	new[38]|new[40]	_	_
7-18	692-700	patients	abstract[38]|abstract[40]|person[41]	new[38]|new[40]|giv[41]	coref	16-19[144_41]
7-19	701-705	with	abstract[38]|abstract[40]|person[41]	new[38]|new[40]|giv[41]	_	_
7-20	706-715	confirmed	abstract[38]|abstract[40]|person[41]|abstract[42]	new[38]|new[40]|giv[41]|giv[42]	coref	14-6[0_42]
7-21	716-726	aspiration	abstract[38]|abstract[40]|person[41]|abstract[42]	new[38]|new[40]|giv[41]|giv[42]	_	_
7-22	727-728	.	_	_	_	_

#Text=In the United Kingdom ( UK ) , national guidelines recommend people with acute stroke have their swallow screened within 4 h of hospital admission by a specifically trained healthcare professional and , if dysphagia is suspected , the person should have a specialist swallow assessment by a speech and language therapist ( SLT ) within 72 h of admission ( Supplementary Table S1 : Summary of Royal College of Physicians ( RCP ) Clinical Guideline for Stroke ) .
8-1	729-731	In	_	_	_	_
8-2	732-735	the	place[43]	new[43]	_	_
8-3	736-742	United	place[43]	new[43]	_	_
8-4	743-750	Kingdom	place[43]	new[43]	_	_
8-5	751-752	(	_	_	_	_
8-6	753-755	UK	place	new	_	_
8-7	756-757	)	_	_	_	_
8-8	758-759	,	_	_	_	_
8-9	760-768	national	abstract[45]	new[45]	_	_
8-10	769-779	guidelines	abstract[45]	new[45]	_	_
8-11	780-789	recommend	_	_	_	_
8-12	790-796	people	person[46]	new[46]	ana	8-17[0_46]
8-13	797-801	with	person[46]	new[46]	_	_
8-14	802-807	acute	person[46]|event[47]	new[46]|giv[47]	coref	8-78[0_47]
8-15	808-814	stroke	person[46]|event[47]	new[46]|giv[47]	_	_
8-16	815-819	have	_	_	_	_
8-17	820-825	their	person|animal[49]	giv|new[49]	coref|coref	8-45[0_49]|8-45[0_49]
8-18	826-833	swallow	animal[49]	new[49]	_	_
8-19	834-842	screened	_	_	_	_
8-20	843-849	within	_	_	_	_
8-21	850-851	4	quantity[50]	new[50]	_	_
8-22	852-853	h	quantity[50]	new[50]	_	_
8-23	854-856	of	quantity[50]	new[50]	_	_
8-24	857-865	hospital	quantity[50]|place|event[52]	new[50]|giv|new[52]	coref|coref	8-60[0_52]|8-60[0_52]
8-25	866-875	admission	quantity[50]|event[52]	new[50]|new[52]	_	_
8-26	876-878	by	quantity[50]|event[52]	new[50]|new[52]	_	_
8-27	879-880	a	quantity[50]|event[52]	new[50]|new[52]	_	_
8-28	881-893	specifically	quantity[50]|event[52]	new[50]|new[52]	_	_
8-29	894-901	trained	quantity[50]|event[52]	new[50]|new[52]	_	_
8-30	902-912	healthcare	quantity[50]|event[52]|organization	new[50]|new[52]|new	_	_
8-31	913-925	professional	quantity[50]|event[52]	new[50]|new[52]	_	_
8-32	926-929	and	_	_	_	_
8-33	930-931	,	_	_	_	_
8-34	932-934	if	_	_	_	_
8-35	935-944	dysphagia	abstract	giv	coref	16-21
8-36	945-947	is	_	_	_	_
8-37	948-957	suspected	_	_	_	_
8-38	958-959	,	_	_	_	_
8-39	960-963	the	person[55]	new[55]	_	_
8-40	964-970	person	person[55]	new[55]	_	_
8-41	971-977	should	_	_	_	_
8-42	978-982	have	_	_	_	_
8-43	983-984	a	abstract[57]	new[57]	coref	9-20[76_57]
8-44	985-995	specialist	abstract[57]	new[57]	_	_
8-45	996-1003	swallow	animal|abstract[57]	giv|new[57]	coref	10-24
8-46	1004-1014	assessment	abstract[57]	new[57]	_	_
8-47	1015-1017	by	abstract[57]	new[57]	_	_
8-48	1018-1019	a	abstract[57]|abstract[58]	new[57]|new[58]	_	_
8-49	1020-1026	speech	abstract[57]|abstract[58]	new[57]|new[58]	_	_
8-50	1027-1030	and	abstract[57]	new[57]	_	_
8-51	1031-1039	language	abstract[57]|abstract|person[60]	new[57]|new|new[60]	appos|appos	8-54[0_60]|8-54[0_60]
8-52	1040-1049	therapist	abstract[57]|person[60]	new[57]|new[60]	_	_
8-53	1050-1051	(	abstract[57]	new[57]	_	_
8-54	1052-1055	SLT	abstract[57]|person	new[57]|giv	_	_
8-55	1056-1057	)	abstract[57]	new[57]	_	_
8-56	1058-1064	within	abstract[57]	new[57]	_	_
8-57	1065-1067	72	abstract[57]|quantity[62]	new[57]|new[62]	_	_
8-58	1068-1069	h	abstract[57]|quantity[62]	new[57]|new[62]	_	_
8-59	1070-1072	of	abstract[57]|quantity[62]	new[57]|new[62]	_	_
8-60	1073-1082	admission	abstract[57]|quantity[62]|event	new[57]|new[62]|giv	_	_
8-61	1083-1084	(	_	_	_	_
8-62	1085-1098	Supplementary	abstract[64]	new[64]	_	_
8-63	1099-1104	Table	abstract[64]	new[64]	_	_
8-64	1105-1107	S1	_	_	_	_
8-65	1108-1109	:	_	_	_	_
8-66	1110-1117	Summary	abstract[65]	new[65]	_	_
8-67	1118-1120	of	abstract[65]	new[65]	_	_
8-68	1121-1126	Royal	abstract[65]|organization[66]	new[65]|new[66]	_	_
8-69	1127-1134	College	abstract[65]|organization[66]	new[65]|new[66]	_	_
8-70	1135-1137	of	abstract[65]|organization[66]	new[65]|new[66]	_	_
8-71	1138-1148	Physicians	abstract[65]|organization[66]|person	new[65]|new[66]|new	_	_
8-72	1149-1150	(	_	_	_	_
8-73	1151-1154	RCP	place	new	coref	12-2
8-74	1155-1156	)	_	_	_	_
8-75	1157-1165	Clinical	abstract[69]	new[69]	coref	12-1[101_69]
8-76	1166-1175	Guideline	abstract[69]	new[69]	_	_
8-77	1176-1179	for	abstract[69]	new[69]	_	_
8-78	1180-1186	Stroke	abstract[69]|abstract	new[69]|giv	coref	12-6
8-79	1187-1188	)	_	_	_	_
8-80	1189-1190	.	_	_	_	_

#Text=There is increasing evidence that early dysphagia screening is associated with reduced odds of SAP and that delays in SLT assessment increase pneumonia incidence by 1 % per day of delay .
9-1	1191-1196	There	_	_	_	_
9-2	1197-1199	is	_	_	_	_
9-3	1200-1210	increasing	_	_	_	_
9-4	1211-1219	evidence	abstract[71]	new[71]	coref	12-11[104_71]
9-5	1220-1224	that	abstract[71]	new[71]	_	_
9-6	1225-1230	early	abstract[71]|abstract[72]	new[71]|new[72]	coref	10-5[0_72]
9-7	1231-1240	dysphagia	abstract[71]|abstract[72]	new[71]|new[72]	_	_
9-8	1241-1250	screening	abstract[71]|abstract[72]	new[71]|new[72]	_	_
9-9	1251-1253	is	abstract[71]	new[71]	_	_
9-10	1254-1264	associated	abstract[71]	new[71]	_	_
9-11	1265-1269	with	abstract[71]	new[71]	_	_
9-12	1270-1277	reduced	abstract[71]|abstract[73]	new[71]|new[73]	_	_
9-13	1278-1282	odds	abstract[71]|abstract[73]	new[71]|new[73]	_	_
9-14	1283-1285	of	abstract[71]|abstract[73]	new[71]|new[73]	_	_
9-15	1286-1289	SAP	abstract[71]|abstract[73]|abstract	new[71]|new[73]|giv	coref	9-23
9-16	1290-1293	and	abstract[71]	new[71]	_	_
9-17	1294-1298	that	abstract[71]	new[71]	_	_
9-18	1299-1305	delays	abstract[71]	new[71]	_	_
9-19	1306-1308	in	_	_	_	_
9-20	1309-1312	SLT	abstract|abstract[76]	new|giv[76]	coref|coref|coref|coref	10-22[89_76]|13-7[116_0]|10-22[89_76]|13-7[116_0]
9-21	1313-1323	assessment	abstract[76]	giv[76]	_	_
9-22	1324-1332	increase	_	_	_	_
9-23	1333-1342	pneumonia	abstract|abstract[78]	giv|new[78]	coref|coref	16-17|16-17
9-24	1343-1352	incidence	abstract[78]	new[78]	_	_
9-25	1353-1355	by	_	_	_	_
9-26	1356-1357	1	quantity[79]	new[79]	_	_
9-27	1358-1359	%	quantity[79]	new[79]	_	_
9-28	1360-1363	per	quantity[79]	new[79]	_	_
9-29	1364-1367	day	quantity[79]|time[80]	new[79]|new[80]	_	_
9-30	1368-1370	of	quantity[79]|time[80]	new[79]|new[80]	_	_
9-31	1371-1376	delay	quantity[79]|time[80]|abstract	new[79]|new[80]|new	_	_
9-32	1377-1378	.	_	_	_	_

#Text=The type of dysphagia screening protocol ( DSP ) used varies widely and there is limited information about the components of the specialist swallow assessment .
10-1	1379-1382	The	abstract[82]	new[82]	_	_
10-2	1383-1387	type	abstract[82]	new[82]	_	_
10-3	1388-1390	of	abstract[82]	new[82]	_	_
10-4	1391-1400	dysphagia	abstract[82]|abstract[84]	new[82]|new[84]	appos	10-8[0_84]
10-5	1401-1410	screening	abstract[82]|abstract|abstract[84]	new[82]|giv|new[84]	coref	11-1
10-6	1411-1419	protocol	abstract[82]|abstract[84]	new[82]|new[84]	_	_
10-7	1420-1421	(	_	_	_	_
10-8	1422-1425	DSP	abstract	giv	coref	12-14[106_0]
10-9	1426-1427	)	_	_	_	_
10-10	1428-1432	used	_	_	_	_
10-11	1433-1439	varies	_	_	_	_
10-12	1440-1446	widely	_	_	_	_
10-13	1447-1450	and	_	_	_	_
10-14	1451-1456	there	_	_	_	_
10-15	1457-1459	is	_	_	_	_
10-16	1460-1467	limited	abstract[86]	new[86]	_	_
10-17	1468-1479	information	abstract[86]	new[86]	_	_
10-18	1480-1485	about	abstract[86]	new[86]	_	_
10-19	1486-1489	the	abstract[86]|abstract[87]	new[86]|new[87]	_	_
10-20	1490-1500	components	abstract[86]|abstract[87]	new[86]|new[87]	_	_
10-21	1501-1503	of	abstract[86]|abstract[87]	new[86]|new[87]	_	_
10-22	1504-1507	the	abstract[86]|abstract[87]|abstract[89]	new[86]|new[87]|giv[89]	coref	13-3[115_89]
10-23	1508-1518	specialist	abstract[86]|abstract[87]|abstract[89]	new[86]|new[87]|giv[89]	_	_
10-24	1519-1526	swallow	abstract[86]|abstract[87]|animal|abstract[89]	new[86]|new[87]|giv|giv[89]	_	_
10-25	1527-1537	assessment	abstract[86]|abstract[87]|abstract[89]	new[86]|new[87]|giv[89]	_	_
10-26	1538-1539	.	_	_	_	_

#Text=Screening protocols can vary from informal screens to validated protocols that assess with water only and stepwise screens that provide separate evaluations for non-fluids and fluids .
11-1	1540-1549	Screening	abstract|abstract[91]	giv|new[91]	coref|coref|coref|coref	11-9[93_91]|20-6[181_0]|11-9[93_91]|20-6[181_0]
11-2	1550-1559	protocols	abstract[91]	new[91]	_	_
11-3	1560-1563	can	_	_	_	_
11-4	1564-1568	vary	_	_	_	_
11-5	1569-1573	from	_	_	_	_
11-6	1574-1582	informal	object[92]	new[92]	coref	11-15[95_92]
11-7	1583-1590	screens	object[92]	new[92]	_	_
11-8	1591-1593	to	object[92]	new[92]	_	_
11-9	1594-1603	validated	object[92]|abstract[93]	new[92]|giv[93]	coref	12-37[112_93]
11-10	1604-1613	protocols	object[92]|abstract[93]	new[92]|giv[93]	_	_
11-11	1614-1618	that	_	_	_	_
11-12	1619-1625	assess	_	_	_	_
11-13	1626-1630	with	_	_	_	_
11-14	1631-1636	water	substance	new	coref	12-22
11-15	1637-1641	only	object[95]	giv[95]	_	_
11-16	1642-1645	and	object[95]	giv[95]	_	_
11-17	1646-1654	stepwise	object[95]	giv[95]	_	_
11-18	1655-1662	screens	object[95]	giv[95]	_	_
11-19	1663-1667	that	_	_	_	_
11-20	1668-1675	provide	_	_	_	_
11-21	1676-1684	separate	abstract[96]	new[96]	coref	15-1[133_96]
11-22	1685-1696	evaluations	abstract[96]	new[96]	_	_
11-23	1697-1700	for	_	_	_	_
11-24	1701-1711	non-fluids	substance	new	_	_
11-25	1712-1715	and	_	_	_	_
11-26	1716-1722	fluids	substance	new	coref	13-17[120_0]
11-27	1723-1724	.	_	_	_	_

#Text=The RCP Clinical Guideline for Stroke state that there is good evidence that a multi-item DSP that includes at least a water test of 10 teaspoons and a lingual motor test is more accurate than screening protocols with a single item , but do not recommend a standardised screen .
12-1	1725-1728	The	abstract[101]	giv[101]	_	_
12-2	1729-1732	RCP	place|abstract[101]	giv|giv[101]	_	_
12-3	1733-1741	Clinical	substance|abstract[101]	new|giv[101]	_	_
12-4	1742-1751	Guideline	abstract[101]	giv[101]	_	_
12-5	1752-1755	for	abstract[101]	giv[101]	_	_
12-6	1756-1762	Stroke	abstract[101]|abstract|abstract[103]	giv[101]|giv|new[103]	coref|coref	19-23[176_0]|19-23[176_0]
12-7	1763-1768	state	abstract[101]|abstract[103]	giv[101]|new[103]	_	_
12-8	1769-1773	that	_	_	_	_
12-9	1774-1779	there	_	_	_	_
12-10	1780-1782	is	_	_	_	_
12-11	1783-1787	good	abstract[104]	giv[104]	coref	17-4[146_104]
12-12	1788-1796	evidence	abstract[104]	giv[104]	_	_
12-13	1797-1801	that	_	_	_	_
12-14	1802-1803	a	abstract[106]	giv[106]	_	_
12-15	1804-1814	multi-item	abstract|abstract[106]	new|giv[106]	_	_
12-16	1815-1818	DSP	abstract[106]	giv[106]	_	_
12-17	1819-1823	that	_	_	_	_
12-18	1824-1832	includes	_	_	_	_
12-19	1833-1835	at	_	_	_	_
12-20	1836-1841	least	abstract[108]	new[108]	_	_
12-21	1842-1843	a	abstract[108]	new[108]	_	_
12-22	1844-1849	water	substance|abstract[108]	giv|new[108]	_	_
12-23	1850-1854	test	abstract[108]	new[108]	_	_
12-24	1855-1857	of	abstract[108]	new[108]	_	_
12-25	1858-1860	10	abstract[108]|quantity[109]	new[108]|new[109]	_	_
12-26	1861-1870	teaspoons	abstract[108]|quantity[109]	new[108]|new[109]	_	_
12-27	1871-1874	and	abstract[108]	new[108]	_	_
12-28	1875-1876	a	abstract[108]|abstract[111]	new[108]|new[111]	_	_
12-29	1877-1884	lingual	abstract[108]|abstract[111]	new[108]|new[111]	_	_
12-30	1885-1890	motor	abstract[108]|object|abstract[111]	new[108]|new|new[111]	_	_
12-31	1891-1895	test	abstract[108]|abstract[111]	new[108]|new[111]	_	_
12-32	1896-1898	is	_	_	_	_
12-33	1899-1903	more	_	_	_	_
12-34	1904-1912	accurate	_	_	_	_
12-35	1913-1917	than	_	_	_	_
12-36	1918-1927	screening	_	_	_	_
12-37	1928-1937	protocols	abstract[112]	giv[112]	_	_
12-38	1938-1942	with	abstract[112]	giv[112]	_	_
12-39	1943-1944	a	abstract[112]|abstract[113]	giv[112]|new[113]	_	_
12-40	1945-1951	single	abstract[112]|abstract[113]	giv[112]|new[113]	_	_
12-41	1952-1956	item	abstract[112]|abstract[113]	giv[112]|new[113]	_	_
12-42	1957-1958	,	_	_	_	_
12-43	1959-1962	but	_	_	_	_
12-44	1963-1965	do	_	_	_	_
12-45	1966-1969	not	_	_	_	_
12-46	1970-1979	recommend	_	_	_	_
12-47	1980-1981	a	abstract[114]	new[114]	_	_
12-48	1982-1994	standardised	abstract[114]	new[114]	_	_
12-49	1995-2001	screen	abstract[114]	new[114]	_	_
12-50	2002-2003	.	_	_	_	_

#Text=Typically , a swallow assessment by a SLT comprises a cranial nerve examination , trials of different fluids and diet textures and compensatory strategies .
13-1	2004-2013	Typically	_	_	_	_
13-2	2014-2015	,	_	_	_	_
13-3	2016-2017	a	abstract[115]	giv[115]	coref	15-7[135_115]
13-4	2018-2025	swallow	abstract[115]	giv[115]	_	_
13-5	2026-2036	assessment	abstract[115]	giv[115]	_	_
13-6	2037-2039	by	abstract[115]	giv[115]	_	_
13-7	2040-2041	a	abstract[115]|abstract[116]	giv[115]|giv[116]	_	_
13-8	2042-2045	SLT	abstract[115]|abstract[116]	giv[115]|giv[116]	_	_
13-9	2046-2055	comprises	_	_	_	_
13-10	2056-2057	a	event[117]|abstract[118]	new[117]|new[118]	ana|coref|ana|coref	14-1[0_118]|14-11[127_117]|14-1[0_118]|14-11[127_117]
13-11	2058-2065	cranial	event[117]|abstract[118]	new[117]|new[118]	_	_
13-12	2066-2071	nerve	event[117]|abstract[118]	new[117]|new[118]	_	_
13-13	2072-2083	examination	event[117]|abstract[118]	new[117]|new[118]	_	_
13-14	2084-2085	,	abstract[118]	new[118]	_	_
13-15	2086-2092	trials	abstract[118]|abstract[119]	new[118]|new[119]	_	_
13-16	2093-2095	of	abstract[118]|abstract[119]	new[118]|new[119]	_	_
13-17	2096-2105	different	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
13-18	2106-2112	fluids	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
13-19	2113-2116	and	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
13-20	2117-2121	diet	abstract[118]|abstract[119]|substance[120]|object|abstract[122]	new[118]|new[119]|giv[120]|new|new[122]	_	_
13-21	2122-2130	textures	abstract[118]|abstract[119]|substance[120]|abstract[122]	new[118]|new[119]|giv[120]|new[122]	_	_
13-22	2131-2134	and	abstract[118]|abstract[119]|substance[120]	new[118]|new[119]|giv[120]	_	_
13-23	2135-2147	compensatory	abstract[118]|abstract[119]|substance[120]|abstract[123]	new[118]|new[119]|giv[120]|new[123]	_	_
13-24	2148-2158	strategies	abstract[118]|abstract[119]|substance[120]|abstract[123]	new[118]|new[119]|giv[120]|new[123]	_	_
13-25	2159-2160	.	_	_	_	_

#Text=Those suspected of risk of aspiration should be assessed for instrumental examination using techniques such as videofluoroscopic swallowing examination ( VFSE ) or fibreoptic endoscopic evaluation of swallowing ( FEES ) .
14-1	2161-2166	Those	abstract	giv	_	_
14-2	2167-2176	suspected	_	_	_	_
14-3	2177-2179	of	_	_	_	_
14-4	2180-2184	risk	abstract[125]	new[125]	_	_
14-5	2185-2187	of	abstract[125]	new[125]	_	_
14-6	2188-2198	aspiration	abstract[125]|abstract	new[125]|giv	_	_
14-7	2199-2205	should	_	_	_	_
14-8	2206-2208	be	_	_	_	_
14-9	2209-2217	assessed	_	_	_	_
14-10	2218-2221	for	_	_	_	_
14-11	2222-2234	instrumental	event[127]	giv[127]	coref	14-17[129_127]
14-12	2235-2246	examination	event[127]	giv[127]	_	_
14-13	2247-2252	using	_	_	_	_
14-14	2253-2263	techniques	abstract[128]	new[128]	_	_
14-15	2264-2268	such	abstract[128]	new[128]	_	_
14-16	2269-2271	as	abstract[128]	new[128]	_	_
14-17	2272-2289	videofluoroscopic	abstract[128]|event[129]	new[128]|giv[129]	_	_
14-18	2290-2300	swallowing	abstract[128]|event[129]	new[128]|giv[129]	_	_
14-19	2301-2312	examination	abstract[128]|event[129]	new[128]|giv[129]	_	_
14-20	2313-2314	(	_	_	_	_
14-21	2315-2319	VFSE	object	new	_	_
14-22	2320-2321	)	_	_	_	_
14-23	2322-2324	or	_	_	_	_
14-24	2325-2335	fibreoptic	abstract[131]	new[131]	_	_
14-25	2336-2346	endoscopic	abstract[131]	new[131]	_	_
14-26	2347-2357	evaluation	abstract[131]	new[131]	_	_
14-27	2358-2360	of	_	_	_	_
14-28	2361-2371	swallowing	_	_	_	_
14-29	2372-2373	(	_	_	_	_
14-30	2374-2378	FEES	abstract	new	_	_
14-31	2379-2380	)	_	_	_	_
14-32	2381-2382	.	_	_	_	_

#Text=These assessments provide direct imaging for assessment of the swallowing physiology and help to predict outcomes and treatment planning .
15-1	2383-2388	These	abstract[133]	giv[133]	_	_
15-2	2389-2400	assessments	abstract[133]	giv[133]	_	_
15-3	2401-2408	provide	_	_	_	_
15-4	2409-2415	direct	abstract[134]	new[134]	_	_
15-5	2416-2423	imaging	abstract[134]	new[134]	_	_
15-6	2424-2427	for	abstract[134]	new[134]	_	_
15-7	2428-2438	assessment	abstract[134]|abstract[135]	new[134]|giv[135]	coref	19-17[0_135]
15-8	2439-2441	of	abstract[134]|abstract[135]	new[134]|giv[135]	_	_
15-9	2442-2445	the	abstract[134]|abstract[135]|abstract[136]	new[134]|giv[135]|new[136]	_	_
15-10	2446-2456	swallowing	abstract[134]|abstract[135]|abstract[136]	new[134]|giv[135]|new[136]	_	_
15-11	2457-2467	physiology	abstract[134]|abstract[135]|abstract[136]	new[134]|giv[135]|new[136]	_	_
15-12	2468-2471	and	_	_	_	_
15-13	2472-2476	help	_	_	_	_
15-14	2477-2479	to	_	_	_	_
15-15	2480-2487	predict	_	_	_	_
15-16	2488-2496	outcomes	event[137]	giv[137]	_	_
15-17	2497-2500	and	event[137]	giv[137]	_	_
15-18	2501-2510	treatment	event[137]|event|event[139]	giv[137]|new|new[139]	coref|coref	18-23[159_0]|18-23[159_0]
15-19	2511-2519	planning	event[137]|event[139]	giv[137]|new[139]	_	_
15-20	2520-2521	.	_	_	_	_

#Text=A range of medical interventions and clinical processes may also be associated with the risk of SAP in patients with dysphagia .
16-1	2522-2523	A	_	_	_	_
16-2	2524-2529	range	_	_	_	_
16-3	2530-2532	of	_	_	_	_
16-4	2533-2540	medical	event[140]	new[140]	_	_
16-5	2541-2554	interventions	event[140]	new[140]	_	_
16-6	2555-2558	and	_	_	_	_
16-7	2559-2567	clinical	abstract[141]	new[141]	_	_
16-8	2568-2577	processes	abstract[141]	new[141]	_	_
16-9	2578-2581	may	_	_	_	_
16-10	2582-2586	also	_	_	_	_
16-11	2587-2589	be	_	_	_	_
16-12	2590-2600	associated	_	_	_	_
16-13	2601-2605	with	_	_	_	_
16-14	2606-2609	the	abstract[142]	new[142]	coref	17-24[153_142]
16-15	2610-2614	risk	abstract[142]	new[142]	_	_
16-16	2615-2617	of	abstract[142]	new[142]	_	_
16-17	2618-2621	SAP	abstract[142]|abstract	new[142]|giv	coref	17-27
16-18	2622-2624	in	abstract[142]	new[142]	_	_
16-19	2625-2633	patients	abstract[142]|person[144]	new[142]|giv[144]	coref	17-22[0_144]
16-20	2634-2638	with	abstract[142]|person[144]	new[142]|giv[144]	_	_
16-21	2639-2648	dysphagia	abstract[142]|person[144]|abstract	new[142]|giv[144]|giv	coref	17-18
16-22	2649-2650	.	_	_	_	_

#Text=There is emerging evidence for the use of preventative measures such as screening for stroke-induced immunosuppression and dysphagia , for identifying patients at high risk for SAP .
17-1	2651-2656	There	_	_	_	_
17-2	2657-2659	is	_	_	_	_
17-3	2660-2668	emerging	_	_	_	_
17-4	2669-2677	evidence	abstract[146]	giv[146]	_	_
17-5	2678-2681	for	abstract[146]	giv[146]	_	_
17-6	2682-2685	the	abstract[146]|abstract[147]	giv[146]|new[147]	_	_
17-7	2686-2689	use	abstract[146]|abstract[147]	giv[146]|new[147]	_	_
17-8	2690-2692	of	abstract[146]|abstract[147]	giv[146]|new[147]	_	_
17-9	2693-2705	preventative	abstract[146]|abstract[147]|abstract[148]	giv[146]|new[147]|new[148]	_	_
17-10	2706-2714	measures	abstract[146]|abstract[147]|abstract[148]	giv[146]|new[147]|new[148]	_	_
17-11	2715-2719	such	_	_	_	_
17-12	2720-2722	as	_	_	_	_
17-13	2723-2732	screening	_	_	_	_
17-14	2733-2736	for	_	_	_	_
17-15	2737-2751	stroke-induced	abstract[149]|abstract[150]	giv[149]|giv[150]	_	_
17-16	2752-2769	immunosuppression	abstract[149]|abstract[150]	giv[149]|giv[150]	_	_
17-17	2770-2773	and	abstract[150]	giv[150]	_	_
17-18	2774-2783	dysphagia	abstract[150]|abstract	giv[150]|giv	coref	18-41
17-19	2784-2785	,	_	_	_	_
17-20	2786-2789	for	_	_	_	_
17-21	2790-2801	identifying	_	_	_	_
17-22	2802-2810	patients	person	giv	coref	18-39[167_0]
17-23	2811-2813	at	_	_	_	_
17-24	2814-2818	high	abstract[153]	giv[153]	_	_
17-25	2819-2823	risk	abstract[153]	giv[153]	_	_
17-26	2824-2827	for	abstract[153]	giv[153]	_	_
17-27	2828-2831	SAP	abstract[153]|abstract	giv[153]|giv	coref	18-37[166_0]
17-28	2832-2833	.	_	_	_	_

#Text=Further studies are needed to test this and screening for oral aerobic Gram-negative bacteria as well as the need to evaluate if treatment with proton pump inhibitors and nasogastric tubes ( NGT ) are associated with SAP in patients with dysphagia .
18-1	2834-2841	Further	event[155]	new[155]	coref	19-10[0_155]
18-2	2842-2849	studies	event[155]	new[155]	_	_
18-3	2850-2853	are	_	_	_	_
18-4	2854-2860	needed	_	_	_	_
18-5	2861-2863	to	_	_	_	_
18-6	2864-2868	test	_	_	_	_
18-7	2869-2873	this	_	_	_	_
18-8	2874-2877	and	_	_	_	_
18-9	2878-2887	screening	_	_	_	_
18-10	2888-2891	for	_	_	_	_
18-11	2892-2896	oral	plant[157]	new[157]	_	_
18-12	2897-2904	aerobic	plant[157]	new[157]	_	_
18-13	2905-2918	Gram-negative	abstract|plant[157]	new|new[157]	_	_
18-14	2919-2927	bacteria	plant[157]	new[157]	_	_
18-15	2928-2930	as	_	_	_	_
18-16	2931-2935	well	_	_	_	_
18-17	2936-2938	as	_	_	_	_
18-18	2939-2942	the	abstract[158]	new[158]	_	_
18-19	2943-2947	need	abstract[158]	new[158]	_	_
18-20	2948-2950	to	_	_	_	_
18-21	2951-2959	evaluate	_	_	_	_
18-22	2960-2962	if	_	_	_	_
18-23	2963-2972	treatment	event[159]	giv[159]	_	_
18-24	2973-2977	with	event[159]	giv[159]	_	_
18-25	2978-2984	proton	event[159]|person|object[162]	giv[159]|new|new[162]	_	_
18-26	2985-2989	pump	event[159]|object|object[162]	giv[159]|new|new[162]	_	_
18-27	2990-3000	inhibitors	event[159]|object[162]	giv[159]|new[162]	_	_
18-28	3001-3004	and	event[159]	giv[159]	_	_
18-29	3005-3016	nasogastric	event[159]|abstract|object[164]	giv[159]|new|new[164]	_	_
18-30	3017-3022	tubes	event[159]|object[164]	giv[159]|new[164]	_	_
18-31	3023-3024	(	_	_	_	_
18-32	3025-3028	NGT	substance	new	_	_
18-33	3029-3030	)	_	_	_	_
18-34	3031-3034	are	_	_	_	_
18-35	3035-3045	associated	_	_	_	_
18-36	3046-3050	with	_	_	_	_
18-37	3051-3054	SAP	abstract[166]	giv[166]	coref	19-29[0_166]
18-38	3055-3057	in	abstract[166]	giv[166]	_	_
18-39	3058-3066	patients	abstract[166]|person[167]	giv[166]|giv[167]	coref	20-15[185_167]
18-40	3067-3071	with	abstract[166]|person[167]	giv[166]|giv[167]	_	_
18-41	3072-3081	dysphagia	abstract[166]|person[167]|abstract	giv[166]|giv[167]|giv	coref	19-21[175_0]
18-42	3082-3083	.	_	_	_	_

#Text=This study forms part of an over-arching series of studies aiming to explore whether variation in assessment and management of dysphagia in acute stroke affects the development of SAP .
19-1	3084-3088	This	abstract[169]	new[169]	coref	22-4[207_169]
19-2	3089-3094	study	abstract[169]	new[169]	_	_
19-3	3095-3100	forms	_	_	_	_
19-4	3101-3105	part	_	_	_	_
19-5	3106-3108	of	_	_	_	_
19-6	3109-3111	an	abstract[170]	new[170]	_	_
19-7	3112-3124	over-arching	abstract[170]	new[170]	_	_
19-8	3125-3131	series	abstract[170]	new[170]	_	_
19-9	3132-3134	of	abstract[170]	new[170]	_	_
19-10	3135-3142	studies	abstract[170]|event	new[170]|giv	_	_
19-11	3143-3149	aiming	_	_	_	_
19-12	3150-3152	to	_	_	_	_
19-13	3153-3160	explore	_	_	_	_
19-14	3161-3168	whether	_	_	_	_
19-15	3169-3178	variation	abstract[172]	new[172]	_	_
19-16	3179-3181	in	abstract[172]	new[172]	_	_
19-17	3182-3192	assessment	abstract[172]|abstract	new[172]|giv	coref	20-9
19-18	3193-3196	and	abstract[172]	new[172]	_	_
19-19	3197-3207	management	abstract[172]|organization[174]	new[172]|new[174]	_	_
19-20	3208-3210	of	abstract[172]|organization[174]	new[172]|new[174]	_	_
19-21	3211-3220	dysphagia	abstract[172]|organization[174]|abstract[175]	new[172]|new[174]|giv[175]	coref	22-23[0_175]
19-22	3221-3223	in	abstract[172]|organization[174]|abstract[175]	new[172]|new[174]|giv[175]	_	_
19-23	3224-3229	acute	abstract[172]|organization[174]|abstract[175]|event[176]	new[172]|new[174]|giv[175]|giv[176]	coref	20-15[0_176]
19-24	3230-3236	stroke	abstract[172]|organization[174]|abstract[175]|event[176]	new[172]|new[174]|giv[175]|giv[176]	_	_
19-25	3237-3244	affects	_	_	_	_
19-26	3245-3248	the	abstract[177]	new[177]	_	_
19-27	3249-3260	development	abstract[177]	new[177]	_	_
19-28	3261-3263	of	abstract[177]	new[177]	_	_
19-29	3264-3267	SAP	abstract[177]|abstract	new[177]|giv	coref	21-17
19-30	3268-3269	.	_	_	_	_

#Text=Interviews with staff responsible for dysphagia screening , assessment and or clinical management of stroke patients were undertaken as part of a mixed methods research design to inform the development of a national survey of hospitals registered in the Sentinel Stroke National Audit Programme ( SSNAP ) database .
20-1	3270-3280	Interviews	event[179]	new[179]	_	_
20-2	3281-3285	with	event[179]	new[179]	_	_
20-3	3286-3291	staff	event[179]|person	new[179]|new	_	_
20-4	3292-3303	responsible	event[179]	new[179]	_	_
20-5	3304-3307	for	_	_	_	_
20-6	3308-3317	dysphagia	abstract[181]	giv[181]	coref	22-18[0_181]
20-7	3318-3327	screening	abstract[181]	giv[181]	_	_
20-8	3328-3329	,	_	_	_	_
20-9	3330-3340	assessment	abstract	giv	_	_
20-10	3341-3344	and	_	_	_	_
20-11	3345-3347	or	_	_	_	_
20-12	3348-3356	clinical	person[183]	new[183]	_	_
20-13	3357-3367	management	person[183]	new[183]	_	_
20-14	3368-3370	of	person[183]	new[183]	_	_
20-15	3371-3377	stroke	person[183]|event|person[185]	new[183]|giv|giv[185]	coref|coref|coref|coref	20-41|22-21[0_185]|20-41|22-21[0_185]
20-16	3378-3386	patients	person[183]|person[185]	new[183]|giv[185]	_	_
20-17	3387-3391	were	_	_	_	_
20-18	3392-3402	undertaken	_	_	_	_
20-19	3403-3405	as	_	_	_	_
20-20	3406-3410	part	_	_	_	_
20-21	3411-3413	of	_	_	_	_
20-22	3414-3415	a	abstract[188]	new[188]	_	_
20-23	3416-3421	mixed	abstract[188]	new[188]	_	_
20-24	3422-3429	methods	abstract|abstract[188]	new|new[188]	_	_
20-25	3430-3438	research	abstract|abstract[188]	new|new[188]	_	_
20-26	3439-3445	design	abstract[188]	new[188]	_	_
20-27	3446-3448	to	_	_	_	_
20-28	3449-3455	inform	_	_	_	_
20-29	3456-3459	the	abstract[189]	new[189]	_	_
20-30	3460-3471	development	abstract[189]	new[189]	_	_
20-31	3472-3474	of	abstract[189]	new[189]	_	_
20-32	3475-3476	a	abstract[189]|abstract[190]	new[189]|new[190]	coref	21-5[0_190]
20-33	3477-3485	national	abstract[189]|abstract[190]	new[189]|new[190]	_	_
20-34	3486-3492	survey	abstract[189]|abstract[190]	new[189]|new[190]	_	_
20-35	3493-3495	of	abstract[189]|abstract[190]	new[189]|new[190]	_	_
20-36	3496-3505	hospitals	abstract[189]|abstract[190]|organization	new[189]|new[190]|new	_	_
20-37	3506-3516	registered	_	_	_	_
20-38	3517-3519	in	_	_	_	_
20-39	3520-3523	the	abstract[195]	new[195]	_	_
20-40	3524-3532	Sentinel	organization|abstract[195]	new|new[195]	_	_
20-41	3533-3539	Stroke	abstract|abstract[195]	giv|new[195]	_	_
20-42	3540-3548	National	event[194]|abstract[195]	new[194]|new[195]	coref	22-15[0_194]
20-43	3549-3554	Audit	event[194]|abstract[195]	new[194]|new[195]	_	_
20-44	3555-3564	Programme	abstract[195]	new[195]	_	_
20-45	3565-3566	(	_	_	_	_
20-46	3567-3572	SSNAP	organization	new	coref	22-34
20-47	3573-3574	)	_	_	_	_
20-48	3575-3583	database	object	new	coref	21-8[201_0]
20-49	3584-3585	.	_	_	_	_

#Text=Statistical analysis of the survey responses with the database will highlight barriers and facilitators for reducing SAP .
21-1	3586-3597	Statistical	abstract[198]	new[198]	_	_
21-2	3598-3606	analysis	abstract[198]	new[198]	_	_
21-3	3607-3609	of	abstract[198]	new[198]	_	_
21-4	3610-3613	the	abstract[198]|abstract[200]	new[198]|new[200]	_	_
21-5	3614-3620	survey	abstract[198]|abstract|abstract[200]	new[198]|giv|new[200]	_	_
21-6	3621-3630	responses	abstract[198]|abstract[200]	new[198]|new[200]	_	_
21-7	3631-3635	with	abstract[198]|abstract[200]	new[198]|new[200]	_	_
21-8	3636-3639	the	abstract[198]|abstract[200]|object[201]	new[198]|new[200]|giv[201]	_	_
21-9	3640-3648	database	abstract[198]|abstract[200]|object[201]	new[198]|new[200]|giv[201]	_	_
21-10	3649-3653	will	_	_	_	_
21-11	3654-3663	highlight	_	_	_	_
21-12	3664-3672	barriers	abstract	new	_	_
21-13	3673-3676	and	_	_	_	_
21-14	3677-3689	facilitators	abstract	new	_	_
21-15	3690-3693	for	_	_	_	_
21-16	3694-3702	reducing	_	_	_	_
21-17	3703-3706	SAP	abstract	giv	_	_
21-18	3707-3708	.	_	_	_	_

#Text=The aim of the interview study was to explore beyond the 4-h and 72-h audit criteria for screening and assessing patients for dysphagia to give a more rounded picture of care beyond the SSNAP performance indicators .
22-1	3709-3712	The	abstract[205]	new[205]	_	_
22-2	3713-3716	aim	abstract[205]	new[205]	_	_
22-3	3717-3719	of	abstract[205]	new[205]	_	_
22-4	3720-3723	the	abstract[205]|abstract[207]	new[205]|giv[207]	_	_
22-5	3724-3733	interview	abstract[205]|event|abstract[207]	new[205]|new|giv[207]	_	_
22-6	3734-3739	study	abstract[205]|abstract[207]	new[205]|giv[207]	_	_
22-7	3740-3743	was	_	_	_	_
22-8	3744-3746	to	_	_	_	_
22-9	3747-3754	explore	_	_	_	_
22-10	3755-3761	beyond	_	_	_	_
22-11	3762-3765	the	abstract[208]	new[208]	_	_
22-12	3766-3769	4-h	abstract[208]	new[208]	_	_
22-13	3770-3773	and	_	_	_	_
22-14	3774-3778	72-h	time|abstract[211]	new|new[211]	_	_
22-15	3779-3784	audit	event|abstract[211]	giv|new[211]	_	_
22-16	3785-3793	criteria	abstract[211]	new[211]	_	_
22-17	3794-3797	for	_	_	_	_
22-18	3798-3807	screening	abstract	giv	_	_
22-19	3808-3811	and	_	_	_	_
22-20	3812-3821	assessing	_	_	_	_
22-21	3822-3830	patients	person	giv	_	_
22-22	3831-3834	for	_	_	_	_
22-23	3835-3844	dysphagia	abstract	giv	_	_
22-24	3845-3847	to	_	_	_	_
22-25	3848-3852	give	_	_	_	_
22-26	3853-3854	a	abstract[215]	new[215]	_	_
22-27	3855-3859	more	abstract[215]	new[215]	_	_
22-28	3860-3867	rounded	abstract[215]	new[215]	_	_
22-29	3868-3875	picture	abstract[215]	new[215]	_	_
22-30	3876-3878	of	abstract[215]	new[215]	_	_
22-31	3879-3883	care	abstract[215]|abstract[216]	new[215]|new[216]	_	_
22-32	3884-3890	beyond	abstract[215]|abstract[216]	new[215]|new[216]	_	_
22-33	3891-3894	the	abstract[215]|abstract[216]|abstract[219]	new[215]|new[216]|new[219]	_	_
22-34	3895-3900	SSNAP	abstract[215]|abstract[216]|abstract|abstract[219]	new[215]|new[216]|giv|new[219]	_	_
22-35	3901-3912	performance	abstract[215]|abstract[216]|abstract|abstract[219]	new[215]|new[216]|new|new[219]	_	_
22-36	3913-3923	indicators	abstract[215]|abstract[216]|abstract[219]	new[215]|new[216]|new[219]	_	_
22-37	3924-3925	.	_	_	_	_
